key: cord-0691762-wxwmdoa6 authors: Yousefi Dehbidi, Maryam; Goodarzi, Nima; Azhdari, Mohammad H.; Doroudian, Mohammad title: Mesenchymal stem cells and their derived exosomes to combat Covid–19 date: 2021-08-07 journal: Rev Med Virol DOI: 10.1002/rmv.2281 sha: 7c7f5ff8de8cd9306c77ad987c66899b54cf08df doc_id: 691762 cord_uid: wxwmdoa6 Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is causing an ongoing pandemic of coronavirus disease 2019 (Covid‐19). Effective therapies are required for the treatment of patients with severe stages of the disease. Mesenchymal stem cells (MSCs) have been evaluated in numerous clinical trials, but present challenges, such as carcinogenic risk and special storage conditions, coupled with insufficient data about their mechanism of action. The majority of unique properties of MSCs are related to their paracrine activity and especially to their exosomes. The impact of MSCs‐derived exosomes (MSC‐Es) on complications of Covid‐19 has been investigated in several studies. MSC‐Es may improve some complications of Covid‐19 such as cytokine storm, acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). Additionally, these exosomes can be evaluated as an applicable nano‐size carrier for antiviral therapeutic agents. Herein, we consider several potential applications of MSCs and their derived exosomes in the treatment of Covid‐19. nucleocapsid (N), and membrane (M)), and about nine accessory proteins. 3, 4 Population-based vaccination strategies represent our current principal defense against this coronavirus. With the onset of mutations and their potential ability to significantly inhibit vaccine efficacy, the development of complementary anti-Covid-19 strategies remains a global priority. [5] [6] [7] Stem cells and their derived exosomes have been shown as effective agents to repair, regenerate, and protect human organs against various body injuries with minimal side effects. 8, 9 The stem cell secretome (SCS) has been demonstrated to have significant anti-fibrotic, anti-inflammatory, immunomodulatory, and angiogenic biological activities [10] [11] [12] Exosomes are nano-sized extracellular vesicles with a diameter of 40-150 nm that are produced by cells in their interior, more precisely in the endosomal compartments of most eukaryotic cells. 13 It was found that MSCs produce exosomes with significant immunomodulatory capacity for tissue restoration. These properties of MSC-ES have been considered the basis for current on-going clinical trials. 14 Many of these MSC-Es contains microRNAs (miRNAs) that regulate crucial cellular functions including cell growth, apoptosis, and host immune responses. 15, 16 It has been proposed that MSC-Es represent an ideal vector for the delivery of targeted anti-viral drugs for the treatment of Covid-19. 17 The cell entry mechanism of SARS-CoV-2 is a subject of interest of recent studies. Angiotensin-converting enzyme 2 (ACE-2) and C-type 209 lecithin (CD209L) act as the main host receptors for binding the S protein of the virus, becoming the first stage of the pathogenesis of Covid-19. The virus enters the host cell either via infusion with the host plasma membrane or via clathrin-dependent and independent endocytosis. 18, 19 It has also been reported that transmembrane protease serine 2 (TMPRSS2) facilitates virus entry into the host cell. 20 The RNA virus itself, after entering into the cell, promotes disruption in host cell immunity. 21 It has been shown that all three types of viral proteins (structural, non-structural, and accessory) have various regulatory impacts on the host cell, 22 Structural and functional proteins of SARS-CoV-2 independently reduce the synthesis of host cell proteins and subsequently decrease the production of interferons (IFN) which significantly impairs the host cell adaptive immune response. Current evidence suggests this is via three mechanisms; (1) Non-structural protein 16 (NSP16) suppresses mRNA splicing and diminishes recognition of viral RNA by intracellular helicase receptors, (2) NSP1 acts as a ribosome gatekeeper to impair cellular translation and specifically promotes viral translation, (3) NSP8, and NSP9 interfere with protein trafficking to the cell membrane. 23, 24 ACE-2, the SARS-CoV-2 receptor, is widely expressed in human organs such as the heart, kidney, gut, liver, and brain which can become involved in systemic infection. [25] [26] [27] The lungs are one of the most commonly affected organ in Covid-19 infection and this is partly explained by the high level of expression of ACE-2, in alveolar type II and capillary endothelial cells. Proposed mechanisms for viral-induced lung injury include -direct injury to the vascular bed and in particular, the capillary endothelial cells that also involves disruption to the reninangiotensin system (RAS) and a fulminant inflammatory response that results in the breakdown of capillary integrity in targeted organs and the progression to the acute respiratory distress syndrome (ARDS), acute lung injury (ALI), fibrosis, and multiple organ failure. 20, [28] [29] [30] In addition to the lung, other organs involved include the heart and presentations with Kawasaki syndrome, acute coronary syndrome, coagulopathies, myocarditis, the brain and cerebrovascular accidents (CVA's) and focused areas of neuro-inflammation and acute kidney and renal failure, the gut and gastrointestinal alterations, the liver and acute liver injury and hepatic dysfunction. [31] [32] [33] [34] [35] During infection, neutrophils, monocytes, and T cells are recruited to the site of infection by following the chemoattractant gradient of inflammatory chemokines and chemokines produced by infected cells. 36 Under severe conditions, lymphocyte and leukocyte counts decrease, whereas inflammation marker (C-reactive protein), lactic dehydrogenase, proinflammatory cytokines and chemokines (interleukin (IL) 1β, IL-6, IL-7, IL-2, tumor necrosis factor (TNF)α, granulocyte-colony stimulating factor (GCSF), interferon gamma-induced protein-10 (CXCL10), and monocyte chemoattractant protein-1) are elevated dramatically. [37] [38] [39] The production of large amounts of proinflammatory cytokines by inflammatory cells leads to cytokine storm resulting in hyperinflammation and subsequently serious lung damage. 37,40 Currently, a small number of therapeutics such as remdesivir, dexamethasone and bamlanivimab plus etesevimab have already been authorized based on the results of randomised controlled trials (RTCs). Further RCTs of therapeutic candidates, including inhaled interferon-beta, baricitinib, tocilizumab, sarilumab, casirivimab plus imdevimab, and tofacitinib all report clinical benefit. 41, 42 It is now well recognised that patients recovering from acute Covid-19 infection are susceptible to develop what is termed long-Covid syndrome. It is estimated that 1:10 individuals are at-risk of persistent disabling symptoms, particularly related to the brain and the lungs, long after the acute infective episode has subsided. 43 It has been postulated that in response to this overwhelming viral systemic infection that there is a dysregulation in our normal reparative pathways. 44 Mesenchymal stem cells (MSC's) with their immunomodulatory and regenerative capacity, make them promising candidates in the treating of both acute infection but also restoring normal organ repair pathways. 45,46 In recent years, MSCs and their therapeutic potential have received much attention. MSCs are non-specialised, multipotent cells, self-renewable cells, and capable of differentiating into specific cell types. MSCs are easily accessible cells that are derived from a variety of sources, including bone marrow, adipose tissues, lung, umbilical cord tissue, dental pulp, placenta, Wharton jelly, fetal liver, and menstrual blood. 47 They can expand to clinical volume and can be stored for repetitive therapeutic usage. 48 MSCs can also modulate the immune system through direct interaction with host immune cells or indirectly by secreting paracrine cytokines. 10 Their paracrine activity is through the secretion of molecules, termed secretome which includes transcription factors, growth factors, cytokines, chemokines, hormones, extracellular vesicles (e.g. exosomes), angiogenic molecules, nucleic acids, and lipid mediators which their biological functions and properties such as migration, angiogenesis, homing, metabolic regulation, anti-inflammation, anti-fibrotic and anti-apoptosis help to regenerate tissues and improve end-organ function. 26,49 MSCs therapy has attracted attention due to their potential immunomodulatory properties through interaction with immune cells, including B and T cells, dendritic cells (DCs), macrophages, neutrophils, and natural killer (NK). For instance, inflammatory factors in the host body modify the properties of MSCs to modulate the immune system. 25, 36 The release of inflammatory mediators in the lung is regulated by the differential activation of damage-associated mo- 55 MSCs also have therapeutic effects on other organs. They reduce encephalitis and recover the blood-brain barrier (BBB) in the brain. 56 In gut, they can regulate inflammation, remodel tissue, and promote the eradication of infections ( Figure 1 ). 20 MSCs have for Covid-19 treatment due to previous clinical outcomes in the treatment of blood, heart, kidney, and lung diseases such as ARDS and fibrosis. 19, 25 In addition, the successful outcome of previous investigations in the treatment of immune-mediated inflammatory diseases such as systemic lupus erythematosus (SLE), graft-versus-host disease (GVHD), and viral infections (e.g. H5N1 and F I G U R E 1 Therapeutic effects of mesenchymal stem cells (MSCs) in combating COVID-19. MSCs can regulate the immune system by changing cell characteristics and releasing chemical compounds. MSCs also have anti-inflammation, anti-microbial, and anti-viral properties by regulating different mechanisms and pathways. SARS-CoV-2 is a multi-organ disease and using MSCs is beneficial for relieving the complications that this virus causes in organs such as the brain, gut, and lung YOUSEFI DEHBIDI ET AL. Table 1 represents clinical trials operated with stem cells for the treatment of Covid-19 patients. Although cell therapy provides numerous advantages, four main challenges still remain; (1) potential tumorigenesis of cytokines secreted by MSCs such as VEGF; (2) Low survival of transplanted MSCs in the body due to their high sensitivity to harsh environmental conditions (e. g. inflammation); (3) risk of obstruction of smalldiameter pulmonary arteries as cells pass through; (4) special requirements of storage at a temperature of −80°C. 37, 62 To address these challenges, exosome therapy is a promising strategy due to its lower tumorigenicity, lack of transmission of secondary infections, easy manipulation, simple storage requirements, and availability. 20 In multicellular organisms, most of the physiological processes occur through intracellular signaling. 63 produced during the programmed cell death-apoptosis. 65, 66 Many types of cells, including immune cells, 64 second, soluble proteins encapsulated inside the vesicles; such as heat shock proteins, chaperones, signaling proteins, cytokines, and interleukins. 68, 69 In addition to the proteins, mRNAs, and micRNAs are other bioactive molecules presenting in exosomes. 70 Depending on the origin of cells' microenvironmental stresses and conditions, exosomes can be wildly diverse in their composition. 71 It has been established that exosomes contain a similar cargo composition to that of the cells that secrete them, indicating that MSC-Es are functionally in accordance with the function of MSCs, 72 Although the mechanism of action of MSC-E have not been fully understood, these outcomes are thought to be related to exosome miRNA cargo. 84 miRNAs are a subclass of small RNAs that can inhibit translation process, cause mRNA decapping and deadenylation. 85 Insilico analysis has shown massive amount of various miRNA cargo in MSC-Es, which includes 258 miRNAs related to cytokines and chemokines and 266 miRNAs for cell death (pyroptosis, apoptosis, and necrosis) genes. 86 Exosomes have attracted increasing attention from drug delivery systems in the past decade owing to their intrinsic properties such as high stability, biodegradability, biocompatibility, prolonged circulation time, low immunogenicity, and the ability to pass blood barriers, all of which represent exosomes an ideal carrier for therapeutic agents such as anti-viral drugs and miRNAs. 88 None. All authors declare no competing interests. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle COVID-19) Dashboard Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic Coronavirus biology and replication: implications for SARS-CoV-2 One year of SARS-CoV-2: How much has the virus changed? Evolution patterns of SARS-CoV-2: Snapshot on its genome variants COVID-19 vaccines: where we stand and challenges ahead Stem cells: past, present, and future A paradigm shift in cellfree approach: the emerging role of MSCs-derived exosomes in regenerative medicine Can mesenchymal stem cell therapy be the interim management of COVID-19? Mesenchymal stem cell microvesicles restore protein permeability across primary cultures of injured human lung microvascular endothelial cells Pluripotency and immunomodulatory signatures of canine induced pluripotent stem cell-derived mesenchymal stromal cells are similar to harvested mesenchymal stromal cells Exosomes: extracellular organelles important in intercellular communication Concise review: MSC-derived exosomes for cell-free therapy microRNAs and the immune response Exosomal microRNAs: novel players in cervical cancer Systematic review of extracellular vesicle-based treatments for lung injury: are EVs a potential therapy for COVID-19? Molecular immune pathogenesis and diagnosis of COVID-19 Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway. iScience Activation and evasion of type I interferon responses by SARS-CoV-2 COVID-19 and the human innate immune system The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapyachieving global consensus and visibility for cellular host-directed therapies Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection Angiotensin-converting enzyme 2: the old door for new severe acute respiratory syndrome coronavirus 2 infection Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia Severe acute lung injury related to COVID-19 infection: a review and the possible role for escin Critical illness and systemic inflammation are key risk factors of severe acute kidney injury in patients with COVID-19 Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms COVID-19-Associated neurological disorders: the potential route of CNS invasion and blood-brain relevance Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy COVID-19 and the liver Immunity and inflammatory biomarkers in COVID-19: a systematic review Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Downregulation of membrane-bound angiotensin converting enzyme 2 (ACE2) receptor has a pivotal role in COVID-19 immunopathology Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes Natural history of COVID-19 and current knowledge on treatment therapeutic options Covid-19: time for a paradigm change Symptoms and functional impairment assessed 8 Months after mild COVID-19 among health care workers Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19 Stem cell therapy for COVID-19: possibilities and challenges Mesenchymal stem cell perspective: cell biology to clinical progress Human mesenchymal stem cellscurrent trends and future prospective Mesenchymal stem cell therapy for COVID-19: present or future Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use Combating COVID-19 with mesenchymal stem cell therapy Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer Exosomeguided phenotypic switch of M1 to M2 macrophages for cutaneous wound healing Mesenchymal stem cells: current clinical progress in ARDS and COVID-19 Danger-associated molecular patterns (DAMPs): the derivatives and triggers of inflammation Lung protection vs. Infection resolution: interleukin 10 Suspected of double-dealing in COVID-19 Stem cell therapy for neurodegenerative diseases: How do stem cells bypass the blood-brain barrier and Home to the brain? Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a Hint for COVID-19 treatment. Engineering (Beijing) Clinical features of patients infected with 2019 novel coronavirus in Wuhan Extracellular vesicles: masters of intercellular communication and potential clinical interventions Cell-cell communication via extracellular membrane vesicles and its role in the immune response Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies Extracellular vesicles: novel communicators in lung diseases Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm Lipid, protein, and MicroRNA composition within mesenchymal stem cell-derived exosomes Functional proteins of mesenchymal stem cell-derived extracellular vesicles Exosome and exosomal microRNA: trafficking, sorting, and function The influence of ionizing radiation on exosome composition, secretion and intercellular communication Mesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy COVID-19 and extracellular vesicles: an intriguing interplay. Kidney and Blood Pressure Research Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies Comparison of immunomodulatory properties of exosomes derived from bone marrow mesenchymal stem cells and dental pulp stem cells Immunomodulatory effects of mesenchymal stromal cells-derived exosome Mesenchymal stem cells overexpressing heme oxygenase-1 ameliorate lipopolysaccharide-induced acute lung injury in rats Anti-inflammatory role of mesenchymal stem cells in an acute lung injury mouse model Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics Mesenchymal stem cell exosomes reverse acute lung injury through Nrf-2/ARE and NF-kappaB signaling pathways Mesenchymal stem cells reverse EMT process through blocking the activation of NF-κB and Hedgehog pathways in LPS-induced acute lung injury MSC-NTF (NurOwn(R)) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model Mesenchymal stem cell-derived extracellular vesicles affect disease outcomes via transfer of microRNAs Mesenchymal stem cellderived extracellular vesicles as therapeutics and as a drug delivery platform Mesenchymal stem cell-derived extracellular vesicles carrying miRNA as a potential multi Target therapy to COVID-19: an in silico analysis Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19 Exosomes as drug delivery systems: endogenous nanovehicles for treatment of systemic lupus erythematosus Nanotechnology based therapeutics for lung disease Nanotechnology in pulmonary medicine Gene editing by extracellular vesicles Exosome therapeutics for COVID-19 and respiratory viruses Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19 Exosome engineering: current progress in cargo loading and targeted delivery Naturally occurring exosome vesicles as potential delivery vehicle for bioactive compounds Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools Design strategies and application progress of therapeutic exosomes Doroudian M. Mesenchymal stem cells and their derived exosomes to combat Covid-19